Benefit-risk assessment of linezolid for serious gram-positive bacterial infections

Drug Safety

Volumn 31, Issue 9, 2008, Pages 753-768

  Falagas, Matthew E ^a,b   Vardakas, Konstantinos Z ^a  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Benefit risk assessment; Gram positive infections; Linezolid, adverse reactions; Linezolid, therapeutic use; Oxazolidinones, adverse reactions; Oxazolidinones, therapeutic use

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOPENICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFADROXIL; CEFPODOXIME; CEFTOBIPROLE; CEFTRIAXONE; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DICLOXACILLIN; LINEZOLID; MACROLIDE; MONOAMINE OXIDASE INHIBITOR; OXACILLIN; PENICILLIN G; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; TEICOPLANIN; TELAVANCIN; TIGECYCLINE; UNINDEXED DRUG; VANCOMYCIN;

ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAEROBIC BACTERIUM; ANEMIA; ANTIBIOTIC RESISTANCE; BACTEREMIA; BACTERIAL INFECTION; BONE MARROW SUPPRESSION; CANDIDIASIS; CATHETER INFECTION; CHILL; CHRONIC DRUG ADMINISTRATION; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONVULSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; EOSINOPHILIA; FATIGUE; GLOSSITIS; GRAM POSITIVE BACTERIUM; GRAM POSITIVE COCCI; HEADACHE; HEMATOLOGIC DISEASE; HOSPITAL INFECTION; HUMAN; HYPERTENSION; INSOMNIA; LACTIC ACIDOSIS; LEUKOPENIA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; MYCOSIS; NAUSEA; NEUROPATHY; OPTIC NERVE DISEASE; PAIN; PARESTHESIA; PATIENT SELECTION; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; RIBOSOME SUBUNIT; RISK BENEFIT ANALYSIS; SEROTONIN SYNDROME; SIDE EFFECT; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; STOMATITIS; TASTE DISORDER; THROMBOCYTOPENIA; TONGUE DISEASE; URINARY TRACT INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS; VENTILATOR ASSOCIATED PNEUMONIA; VOMITING;

ACETAMIDES; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; OXAZOLIDINONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 49749109147     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200831090-00004     Document Type: Review

References (82)

1. Dresser LD, Rybak MJ. The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials. Pharmacotherapy 1998; 18 (3): 456-62
2. Noskin GA, Siddiqui F, Stosor V, et al. In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci. Antimicrob Agents Chemother 1999; 43 (8): 2059-62
3. Lin AH, Murray RW, Vidmar TJ, et al. The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin. Antimicrob Agents Chemother 1997; 41 (10): 2127-31
4. Shinabarger DL, Marotti KR, Murray RW, et al. Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions. Antimicrob Agents Chemother 1997; 41 (10): 2132-6
5. Zurenko GE, Yagi BH, Schaadt RD, et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996; 40 (4): 839-45
6. Perry CM, Jarvis B. Linezolid: a review of its use in the management of serious Gram-positive infections. Pediatr Drugs 2003; 5 (6): 419-29
7. Zyvox® [package insert]. New York (NY); Pfizer Inc.; 2007 [online]. Available from URL: http://www.pfizer.com/pfizer/download/uspi_zyxox.pdf [Accessed on 2007 Jul 15]
8. Andes D, van Ogtrop ML, Peng J, et al. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob Agents Chemother 2002; 46 (11): 3484-9
9. Stalker DJ, Jungbluth GL. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet 2003; 42 (13): 1129-40
10. Stalker DJ, Jungbluth GL, Hopkins NK, et al. Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers. J Antimicrob Chemother 2003; 51 (5): 1239-46
11. Conte Jr JE, Golden JA, Kipps J, et al. Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother 2002; 46 (5): 1475-80
12. Stevens DL, Dotter B, Madaras-Kelly K. A review of linezolid: the first oxazolidinone antibiotic. Expert Rev Anti Infect Ther 2004; 2 (1): 51-9
13. Lovering AM, Zhang J, Bannister GC, et al. Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. J Antimicrob Chemother 2002; 50 (1): 73-7
14. Sabbatani S, Manfredi R, Frank G, et al. Linezolid in the treatment of severe central nervous system infections resistant to recommended antimicrobial compounds. Infez Med 2005; 13 (2): 112-9
15. Rana B, Butcher I, Grigoris P, et al. Linezolid penetration into osteo-articular tissues. J Antimicrob Chemother 2002; 50 (5): 747-50
16. Buerger C, Plock N, Dehghanyar P, et al. Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis. Antimicrob Agents Chemother 2006; 50 (7): 2455-63
17. French G. Safety and tolerability of linezolid. J Antimicrob Chemother 2003; 51 Suppl. 2: ii45-53
18. Slatter JG, Stalker DJ, Feenstra KL, et al. Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C] linezolid to healthy human subjects. Drug Metab Dispos 2001; 29 (8): 1136-45
19. Macgowan AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J Antimicrob Chemother 2003; 51 Suppl. 2: ii17-25
20. Kohno S, Yamaguchi K, Aikawa N, et al. Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan. J Antimicrob Chemother 2007; 60: 1361-9
21. Jaksic B, Martinelli G, Perez-Oteyza J, et al. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis 2006; 42: 597-607
22. Jauregui LE, Babazadeh S, Seltzer E, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 2005; 41: 1407-15
23. Sharpe JN, Shively EH, Polk Jr HC. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. Am J Surg 2005; 189 (4): 425-8
24. Weigelt J, Itani K, Stevens D, et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005; 49 (6): 2260-6
25. Cepeda JA, Whitehouse T, Cooper B. Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study. J Antimicrob Chemother 2004; 53 (2): 345-55
26. Lipsky BA, Itani K, Norden C. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate. Clin Infect Dis 2004; 38 (1): 17-24
27. Raad I, Hachem R, Hanna H, et al. Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections. J Antimicrob Chemother 2004; 53 (4): 646-9
28. Wilcox M, Nathwani D, Dryden M. Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections. J Antimicrob Chemother 2004; 53 (2): 335-44
29. Kaplan SL, Deville JG, Yogev R, et al. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatr Infect Dis J 2003; 22 (8): 677-86
30. Wible K, Tregnaghi M, Bruss J, et al. Linezolid versus cefadroxil in the treatment of skin and skin structure infections in children. Pediatr Infect Dis J 2003; 22 (4): 315-23
31. Wunderink RG, Cammarata SK, Oliphant TH, et al. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Linezolid Nosocomial Pneumonia Study Group. Clin Ther 2003; 25 (3): 980-92
32. San Pedro GS, Cammarata SK, Oliphant TH, et al. Linezolid versus ceftriaxone/cefpodoxime in patients hospitalized for the treatment of Streptococcus pneumoniae pneumonia. Linezolid Community-Acquired Pneumonia Study Group. Scand J Infect Dis 2002; 34 (10): 720-8
33. Stevens DL, Herr D, Lampiris H, et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002; 34 (11): 1481-90
34. Rubinstein E, Cammarata S, Oliphant T, et al. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Linezolid Nosocomial Pneumonia Study Group. Clin Infect Dis 2001; 32 (3): 402-12
35. Cammarata SK, Bermudez M, Golin V, et al. Comparison of linezolid versus ceftriaxone/cefpodoxime in the treatment of hospitalized community-acquired pneumonia [abstract no. 80.008]. In: Program and abstracts of the 9th International Congress on Infectious Diseases, Buenos Aires; International Society of Infectious Diseases; 2000 Apr 10-13, Boston (MA)
36. Cammarata SK, Schueman LK, Timm JA, et al. Oral linezolid in the treatment of community-acquired pneumonia: a phase III trial [abstract no. E73]. In: Program and abstracts of the American Thoracic Society, Toronto; American Thoracic Society; 2000 May 5-10, New York, 654
37. Duvall SE, Seas C, Bruss JB, et al. Comparison of linezolid to oral clarithromycin in the treatment of uncomplicated skin infections: results from a multinational phase III trial [abstract no. 80.005]. In: Program and abstracts of the 9th International Congress on Infectious Diseases, Buenos Aires; International Society of Infectious Diseases; 2000 Apr 10-13, Boston (MA), 181
38. Stevens DL, Smith LG, Bruss JB, et al. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2000; 44 (12): 3408-13
39. Hartman CS, Leach TS, Kaja RW, et al. Linezolid in the treatment of vancomycin-resistant Enterococcus: a dose comparative, multicenter phase III trial [abstract no. 2235]. In: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto; American Society for Microbiology; 2000 Sep 17-20, Washington (DC), 488
40. Falagas ME, Siempos II, Vardakas KZ. Linezolid versus a glycopeptide or β-lactam for treatment of Gram-positive bacterial infections: a meta-analysis of randomized controlled trials. Lancet Infect Dis 2008; 8 (1): 53-66
41. Arnold FW, Summersgill JT, Lajoie AS, et al. A worldwide perspective of atypical pathogens in community-acquired pneumonia. Community-Acquired Pneumonia Organization (CAPO) investigators. Am J Respir Crit Care Med 2007; 175 (10): 1086-93
42. Wunderink RG, Rello J, Cammarata SK, et al. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003; 124: 1789-97
43. Kollef MH, Rello J, Cammarata SK, et al. Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 2004; 30: 388-94
44. Weigelt J, Kaafarani HM, Itani KM, et al. Linezolid eradicates MRSA better than vancomycin from surgical-site infections. Am J Surg 2004; 188 (6): 760-6
45. Birmingham MC, Rayner CR, Meagher AK, et al. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis 2003; 36: 159-68
46. Deville JG, Adler S, Azimi PH, et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. Pediatr Infect Dis J 2003; 22 (9 Suppl.): S158-63
47. Fleishaker DL, Anderson DC, Bruss JB, et al. Clinical efficacy of linezolid (LZD) in the treatment of otitis media [abstract no. 65]. In: Abstracts of the 38th Annual Meeting of the Infectious Diseases Society of America, New Orleans; Infectious Diseases Society of America; 2000 Sep 7-10; Alexandria (VA): 31, 224
48. Kaplan SL, Patterson L, Edwards KM, et al. Linezolid for the treatment of community-acquired pneumonia in hospitalized children. Linezolid Pediatric Pneumonia Study Group. Pediatr Infect Dis J 2001; 20: 488-94
49. Falagas ME, Manta KG, Ntziora F, et al. Linezolid for the treatment of patients with endocarditis: a review of the published evidence. J Antimicrob Chemother 2006; 58: 273-80
50. Senneville E, Legout L, Valette M, et al. Effectiveness and tolerability of prolonged linezolid treatment for chronic osteomyelitis: a retrospective study. Clin Ther 2006; 28 (8): 1155-63
51. Harwood PJ, Talbot C, Dimoutsos M, et al. Early experience with linezolid for infections in orthopaedics. Injury 2006; 37 (9): 818-26
52. Falagas ME, Siempos II, Papagelopoulos PJ, et al. Linezolid for the treatment of adults with bone and joint infections. Int J Antimicrob Agents 2007; 29 (3): 233-9
53. Ntziora F, Falagas ME. Linezolid for the treatment of patients with CNS infection. Ann Pharmacother 2007; 41: 296-308
54. Ntziora F, Falagas ME. Linezolid for the treatment of patients with mycobacterial infection: a systematic review. Int J Tuberc Lung Dis 2007; 11 (6): 606-11
55. US FDA. FDA alert: information for health care professionals regarding linezolid [online]. Available from URL: http://www.fda.gov/cder/drug/InfoSheets/ HCP/linezolidHCP.pdf [Accessed 2007 Mar 22]
56. Rubinstein E, Isturiz R, Standiford HC, et al. Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase III studies. Antimicrob Agents Chemother 2003; 47 (6): 1824-31
57. Kopterides P, Papadomichelakis E, Armaganidis A. Linezolid use associated with lactic acidosis. Scand J Infect Dis 2005; 37 (2): 153-4
58. Narita M, Tsuji BT, Yu VL. Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. Pharmacotherapy 2007; 27 (8): 1189-97
59. Corallo CE, Paull AE. Linezolid-induced neuropathy [letter]. Med J Aust 2002; 177: 332
60. Lee E, Burger S, Shah J, et al. Linezolid-associated toxic optic neuropathy: a report of 2 cases. Clin Infect Dis 2003; 37: 1389-91
61. Saiman L, Goldfarb J, Kaplan SA, et al. Safety and tolerability of linezolid in children. Pediatr Infect Dis J 2003; 22 (9): S193-200
62. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl. 2: S27-72
63. Honeybourne D, Tobin C, Jevons G, et al. Intrapulmonary penetration of linezolid. J Antimicrob Chemother 2003 Jun; 51 (6): 1431-4
64. Ioanas M, Lode H. Linezolid in VAP by MRSA: a better choice? Intensive Care Med 2004; 30: 343-6
65. Micek ST, Dunne M, Kollef MH. Pleuropulmonary complications of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus: importance of treatment with antimicrobials inhibiting exotoxin production. Chest 2005; 128 (4): 2732-8
66. Silverman JA, Mortin LI, Vanpraagh AD, et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modelling and clinical impact. J Infect Dis 2005; 191 (12): 2149-52
67. Fagon J, Patrick H, Haas DW, et al. Treatment of Gram-positive nosocomial pneumonia: prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group. Am J Respir Crit Care Med 2000; 161: 753-62
68. Effectiveness of ceftobiprole for the treatment of patients with hospital-acquired pneumonia [online]. Available from URL: http://www.sys-con. com/read/440454.htm [Accessed on 2008 Feb 12]
69. Effectiveness of ceftobiprole for the treatment of patients with hospital-acquired pneumonia [online]. Available from URL: http://www.redorbit. com/news/health/1170950/theravance_ announces_positive_topline_results_in_phase_3_telavancin_hospitalacquired/index. html [Accessed 2008 Feb 12]
70. Maroko R, Cooper A, Dukart G, et al. Results of phase 3 study comparing a tigecycline (TGC) regimen with an imipenem/ cilastatin (IMI) regimen in treatment of patients (pts) with hospital-acquired pneumonia (HAP) [abstract no. L730]. In: Program and abstracts of the 47th International Congress on Antimicrobial Agents and Chemotherapy; 2007 Sep 17-20, Chicago (IL)
71. Powers JH, Ross DB, Lin D, et al. Linezolid and vancomycin for methicillin-resistant Staphylococcus aureus nosocomial pneumonia: the subtleties of subgroup analyses. Chest 2004; 126 (1): 314-5
72. Kalil AC, Puumala SE, Stoner J. Unresolved questions with the use of linezolid vs vancomycin for nosocomial pneumonia. Chest 2004; 125 (6): 2370-1
73. Vardakas KZ, Ntziora F, Falagas ME. Linezolid: effectiveness and safety for approved and off-label indications. Expert Opin Pharmacother 2007; 8 (14): 2381-400
74. Diekema DJ, Pfaller MA, Schmitz FJ, et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. SENTRY Participants Group. Clin Infect Dis 2001; 32 Suppl. 2: S114-32
75. Richards MJ, Edwards JR, Culver DH, et al. Nosocomial infections in combined medical-surgical intensive care units in the United States. Infect Control Hosp Epidemiol 2000; 21 (8): 510-5
76. Vincent JL, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe: results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 1995; 274 (8): 639-44
77. Doern GV, Jones RN, Pfaller MA, et al. Bacterial pathogens isolated from patients with skin and soft tissue infections: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). SENTRY Study Group (North America). Diagn Microbiol Infect Dis 1999; 34 (1): 65-72
78. Rennie RP, Jones RN, Mutnick AH, et al. Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000). SENTRY Program Study Group (North America). Diagn Microbiol Infect Dis 2003; 45 (4): 287-93
79. Athanassa Z, Siempos II, Falagas ME. Impact of methicillin resistance on the mortality of S. aureus VAP: a systematic review. Eur Respir J 2008 Mar; 31 (3): 625-32
80. Shorr AF, Kunkel MJ, Kollef M. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J Antimicrob Chemother 2005; 56 (5): 923-9
81. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications. A statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005; 111: e394-434
82. Bressler AM, Zimmer SM, Gilmore JL, et al. Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect Dis 2004; 4 (8): 528-31